Biologic Hernia Mesh Linked To Increased Risk of Hernia Recurrence, Study Warns

Researchers found biologic mesh products cost 200 times more than their synthetic counterparts, which carried a much lower risk of hernia recurrence.

The findings of a new study suggest there are higher rates of hernia recurrence and complications with biologic hernia mesh products when compared to synthetic counterparts.

Biologic hernia mesh, or biomesh, is a type of surgical repair mesh made from organic material, such as pig skin, human cadaver skin or other materials, which is promoted as a way to reduce the risk of hernia repair infections associated with synthetic mesh. However, biologic hernia mesh is often substantially more expensive, and there remain many open questions about the clinical effectiveness.

In a report published last week in the medical journal JAMA Surgery, researchers with the Cleveland Clinic found that biologic mesh had a hernia recurrence rate of more than 20%, compared to just under 6% among patients who received synthetic hernia mesh implants at two years following surgery.

The findings come as a growing number of biologic hernia mesh lawsuits are now being filed against the makers of Lifecell Strattice mesh, and other products, alleging that the cross-linked graft device has caused users to experience foreign body responses, infections and other complications, often resulting in the need for risk hernia revision surgery.

Learn More About

Hernia Mesh Lawsuits

Cases reviewed for problems with several types of hernia repair products.

Learn More About this Lawsuit See If You Qualify For Compensation

To compare the rate of hernia recurrence between biologic and synthetic mesh in this new study, researchers conducted a multicenter, single-blinded randomized clinical trial from December 2012 to April 2019, with a follow-up duration of two years. The study involved 253 patients with a median age of 64. Half were implanted with a synthetic mesh and the other half with a biologic mesh.

According to the researchers, synthetic mesh, which is 200 times cheaper, had only 31% of the rate of hernia recurrence as biologic mesh after two years. The recurrence risk with biologic mesh was 20.5%, compared to only 5.6% recurrence among patients with synthetic mesh implants. The average biologic mesh cost $21,539, while the average synthetic mesh cost only $105, the researchers noted.

“Synthetic mesh demonstrated superior 2-year hernia recurrence risk compared with biologic mesh in patients undergoing single-stage repair of contaminated ventral hernias, and both meshes demonstrated similar safety profiles,” the researchers concluded. “The price of biologic mesh was over 200 times that of synthetic mesh for these outcomes.”

Biologic hernia mesh products like the Strattice tissue matrix, which is often referred to as pig skin hernia mesh, is designed to chemically link the proteins in the tissue together. However, the cross-linking mesh has been tied to reports of painful and debilitating complications after the biologic mesh was used during a hernia repair.

From September 1990 through September 2020 the FDA received at least 450 Medical Device Reports (MDRs) linked to problems with the Strattice mesh. Six of those reports included patient deaths, more than 340 were injury reports, and at least 107 indicated malfunctions of the mesh.

Given common questions raised in Strattice mesh lawsuits brought throughout the state of New Jersey, where the manufacturer’s U.S. headquarters are based, centralized pretrial proceedings were established before New Jersey Superior Court Judge John C. Porto in Atlantic County in October, which is intended to reduce duplicative discovery and avoid conflicting pretrial rulings from different judges.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted yesterday)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted 2 days ago)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.